Leaders in the Pharmaceutical Industry to Discuss Opportunities in Nanotechnology
(Nanowerk News) IQPC presents Biopharmaceutical Nanotechnology Scientific Forum taking place August 16-18 in Philadelphia, PA.
This forum will gather leaders from the biotech and pharmaceutical industry to discuss the opportunities in the upcoming year for the discovery, design and development of nanotechnologies for pharmaceuticals.
Expert thought leaders to this conference include:
Jaymin Shah, PhD, Research Fellow, Parenteral Development Centre of Emphasis, Pfizer, Inc.
Steve Ruddy, PhD, Senior Director, Product Development, ELAN
Vivian Bi, PhD, Associate Principal Scientist, Early Development, PAR&D, Astra-Zeneca
Anthony Green, Vice President of Technology Commercialization: Life Sciences, The Nanotechnology Institute
Fuyu Tamanoi, PhD, Professor and Vice Chair, Dept. of Microbiology, Immunology & Molecular Genetics, UCLA
Join them as they present on the following topics:
Nanotechnology for Parenteral Delivery of Poorly Soluble Drugs and Targeting
Integrating Drug Delivery Enablement Technology into Early Pharmaceutical Development
Nanosuspensions as Particulate Drug Formulations in Therapy – Nanosuspension for IV Use
Converging the Science and Business of Nanobiotechnology: Opportunities and Challenges
Nanomachines for Controlled Release of Anticancer Drugs
As various agents go off-patent in the coming months, the biopharmaceutical industry stands to lose drug revenues worth $70-80 billion by 2011, a figure which is expected to skyrocket after that. This conference was designed to assist pharmaceutical and biotech companies take their claim of the market.
IQPC (www.iqpc.com) provides business executives with tailored practical conferences, large-scale events, topical seminars and in-house training programs. Producing over 1,500 events annually around the world, IQPC continues to grow and has offices in cities across six continents including: Berlin, Dubai, London, New York, Sao Paulo, Singapore, Stockholm, Sydney and Toronto.
Printer-friendly
E-mail this article
Daily News Email Digest
News Feeds
Join us on Facebook
Follow us on Twitter
